A Phase 2a Study of Benralizumab for Patients with Eosinophilic Asthma in South Korea and Japan | Zendy

HaeSim Park | Zendy; Mi-Kyeong Kim | Zendy; Nobuyuki Imai | Zendy; Tsutomu Nakanishi | Zendy; Mitsuru Adachi | Zendy; Ken Ohta | Zendy; Yuji Tohda | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

A Phase 2a Study of Benralizumab for Patients with Eosinophilic Asthma in South Korea and Japan

Author(s) -

HaeSim Park,

Mi-Kyeong Kim,

Nobuyuki Imai,

Tsutomu Nakanishi,

Mitsuru Adachi,

Ken Ohta,

Yuji Tohda

Publication year - 2016

Publication title -

international archives of allergy and immunology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.696

H-Index - 100

eISSN - 1423-0097

pISSN - 1018-2438

DOI - 10.1159/000444799

Subject(s) - benralizumab , medicine , asthma , exacerbation , placebo , immunology , interleukin 5 , eosinophil , mepolizumab , gastroenterology , cytokine , interleukin , pathology , alternative medicine

Airway eosinophils are considered to play an important role in the pathogenesis of asthma. Interleukin-5 is believed to be a key cytokine for the development, proliferation and activation of eosinophils. Benralizumab is an anti-interleukin-5 receptor α monoclonal antibody that depletes blood and airway eosinophils. We conducted a phase 2a study in South Korea and Japan to evaluate the effect of benralizumab in an East Asian population. The primary objective was to evaluate the effect of benralizumab in adults with uncontrolled eosinophilic asthma with 2-6 incidences of exacerbations in the past year using a medium/high dose of inhaled corticosteroids and long-acting β2-agonists.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research